Lung | Maryland Oncology Hematology Lung – Maryland Oncology Hematology

Trial ID 20422 DetECT

USOR ID: 20422 Phase N/A
KRAS DetECT: KRAS mutation Detection to Evaluate Eligibility for Clinical Trials

Trial ID 21320 EDP Rockville

NCT04486833
clinicaltrials.gov ID
USOR ID: 21320 Phase I/II
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib

Trial ID APL-101-01

NCT03175224
clinicaltrials.gov ID
Phase I/II

Trial ID 20266

NCT04485013
clinicaltrials.gov ID
USOR ID: 20266 Phase Ib
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies

Trial ID 19151 STAR

NCT03785249
clinicaltrials.gov ID
USOR ID: 19151 Phase II
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Trial ID 20270

NCT04613596
clinicaltrials.gov ID
USOR ID: 20270 Phase II
A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Trial ID 20331 STAR

NCT04620330
clinicaltrials.gov ID
USOR ID: 20331 Phase II
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer

Trial ID 20423

NCT04622007
clinicaltrials.gov ID
USOR ID: 20423 Phase II
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy

Trial ID 20412 STAR

NCT04819100
clinicaltrials.gov ID
USOR ID: 20412 Phase III
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432)

Trial ID 21318 STAR

NCT05170204
clinicaltrials.gov ID
USOR ID: 21318 Phase III
A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER 

Trial ID 21239 STAR

NCT04988295
clinicaltrials.gov ID
USOR ID: 21239 Phase III
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Trial ID 20289 EDP Rockville

NCT04254107
clinicaltrials.gov ID
USOR ID: 20289 Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Trial ID BO41932 / TAPISTRY

NCT04589845
clinicaltrials.gov ID
Phase II

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology